Question 19

Simvastatin use should be limited due to the risk of muscle damage.

The FDA recommends limiting the use of simvastatin primarily because it can lead to serious muscle damage, a condition known as myopathy, which can result in rhabdomyolysis.

A) severe allergic reactions.

While allergic reactions can occur with many medications, they are not the primary concern associated with simvastatin. The FDA's warning focuses specifically on muscle-related risks rather than allergic responses.

B) visual disturbances.

Visual disturbances are not a recognized major risk factor associated with simvastatin use. The primary issues highlighted by the FDA relate to muscle health, not vision.

C) severe anemia.

Severe anemia is not a common side effect of simvastatin and is not mentioned in the FDA recommendations. The focus of the warnings is on the potential for serious muscle injury rather than blood-related conditions.

D) muscle damage.

This is the correct answer as the FDA has expressed concerns about muscle damage related to simvastatin usage. Patients taking this medication may experience myopathy, which can lead to serious complications, necessitating careful monitoring and use restrictions.

Conclusion

The FDA's recommendation to limit simvastatin use is primarily due to the significant risk of muscle damage, which can have severe health implications. Other options, while they may represent potential side effects of medications in general, do not pertain directly to the risks associated with simvastatin as highlighted by the FDA. Thus, option D is clearly the most relevant and accurate choice.